Short-Term HPV Detection Dynamics Across Hormonal Contraceptive Methods in Adolescent Girls and Young Women: A Secondary Analysis of a Randomized Trial in South Africa

Why It Matters

The results suggest that short‑term use of common hormonal contraceptives does not increase HPV risk, informing reproductive‑health guidance for high‑burden regions.

Key Takeaways

• Baseline HPV prevalence 94.9% among participants.
• 16‑week prevalence stayed high at 89.5% across groups.
• No significant differences in acquisition, persistence, or clearance.
• Findings limited by small sample size and short follow‑up.

Pulse Analysis

Human papillomavirus remains a leading cause of cervical disease among adolescent girls and young women in sub‑Saharan Africa, where prevalence often exceeds 80 percent. Understanding how modifiable factors such as hormonal contraception influence HPV dynamics is critical for shaping both vaccination strategies and sexual‑health counseling. Prior observational work hinted at possible links between estrogen‑progestin exposure and viral persistence, prompting researchers to test the hypothesis in a controlled setting.

In this South African trial, 98 participants were randomly assigned to receive either an injectable progestin (norethisterone enanthate), combined oral contraceptive pills, or a combined contraceptive vaginal ring. Cervical swabs collected at enrollment and after 16 weeks underwent genotyping for high‑risk HPV types. Despite an alarmingly high baseline infection rate of 94.9 percent, the follow‑up prevalence fell only marginally to 89.5 percent, and statistical analysis showed no meaningful differences in new infections, ongoing infections, or viral clearance across the three contraceptive groups. These findings challenge the notion that short‑term hormonal exposure materially alters HPV risk in this age cohort.

The study’s implications are twofold. First, it offers reassurance to clinicians and policymakers that offering any of these widely used hormonal methods does not appear to exacerbate short‑term HPV outcomes, supporting continued access to effective contraception without added cervical cancer concerns. Second, the research underscores the need for larger, longer‑duration investigations to capture potential delayed effects and to assess whether similar patterns hold in broader populations. Until such data emerge, public‑health programs should continue emphasizing HPV vaccination and regular screening alongside contraceptive counseling.